IFN-γ and IL-6 are known as the most potent activators, and enhanced levels of both IFN-gamma and IL-6 have been found in patients with PD.311–313 JAK inhibitors can reduce IL-6 or IFN-γ serum levels in patients. This evidence concerns the gene IL6 and Parkinson disease.